biomimx.comCrawled Nov 1, 2026
BiomimX assesses therapeutic efficacy in human disease models to improve preclinical predictions for clinical trials.
The page explains how BiomimX predicts safety and toxicity of therapeutic candidates using human-relevant models to reduce clinical trial risks.
uGut is a miniaturized model of the gastrointestinal tract on a chip, replicating intestinal peristalsis with human gut cells in a 3D environment.
uHeart is a miniaturized, functional human heart model on a chip, developed using uBeat Stretch Platforms to simulate heartbeats with human cardiac cells.
The page describes uHeart, a 3D model of human myocardium, as a tool for screening drug cardiotoxicity early in drug discovery. Testing 12 reference compounds with Accelera Srl, it achieved 83.3% sensitivity, 100% specificity, and 91.6% accuracy.
Elucidate gastrointestinal microbiome interaction at patient specific level.
The company published a paper on a gut-on-chip model that predicts responses to immune checkpoint inhibitors for melanoma using human fecal samples and peristalsis.
Axxam and BiomimX collaborate to advance human-relevant drug discovery using next-generation organ-on-chip technologies.
The Industry Alliance for Microphysiological Systems (IAMPS) launched as the first industry association for organ-on-chip and related technologies.
The page lists posters on organ-on-chip models, including uKnee, uHeart, uGut, and uLung, focusing on osteoarthritis research.
BiomimX Srl originated from research at Politecnico di Milano, founded in 2017 by bioengineers applying microtechnologies to human biology.
The company lists scientific and commercial partners, clients, and affiliations, including AI-RITMIA, funded by the European Commission under Horizon Europe.
BiomimX is pioneer in the generation of predictive models of human organs and pathologies that will revolutionize the way to test drugs and medical devices
